Siemens Healthineers announced yesterday that it has introduced its high-sensitivity troponin I test (TNIH) into certain markets outside the US. The test incorporates Bioventix’s antibody, for which it will receive royalties on Siemens’ product sales. This removes one of the market’s main concerns and downside risk to the share price – how to bridge the potential gap between the loss of a c.£0.9m royalty stream from a customer using its NT-proBNP antibodies, whic
10 May 2017
Downside risk now removed....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Downside risk now removed....
Bioventix Plc (BVXP:LON) | 4,425 -2212.5 (-1.1%) | Mkt Cap: 231.0m
- Published:
10 May 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
6
Siemens Healthineers announced yesterday that it has introduced its high-sensitivity troponin I test (TNIH) into certain markets outside the US. The test incorporates Bioventix’s antibody, for which it will receive royalties on Siemens’ product sales. This removes one of the market’s main concerns and downside risk to the share price – how to bridge the potential gap between the loss of a c.£0.9m royalty stream from a customer using its NT-proBNP antibodies, whic